Hypotensive effect of long-term levodopa in patients with Parkinson's disease. 1990

S Iwasaki, and K Hamaguchi, and A Iwasaki, and M Takakusagi, and Y Narabayashi
Department of Neurology, Saitama Medical School, Japan.

To study the hypotensive effect of L-dopa in patients with Parkinson's disease on long-term L-dopa, the blood pressure (BP) was measured in 14 patients and 6 controls before 100 mg L-dopa plus decarboxylase inhibitor and for up to 180 min after dosing. Plasma monoamines and motor functions were assessed. The mean BP was reduced between 60 and 180 min after dosing in the patients, whereas such a reduction was not observed in 5 patients from whom L-dopa was withheld and in controls who showed a high ratio of plasma dopamine compared to plasma L-dopa after dosing. The L-dopa-induced reduction in BP was thought to be due to a central nervous mechanism.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D011597 Psychomotor Performance The coordination of a sensory or ideational (cognitive) process and a motor activity. Perceptual Motor Performance,Sensory Motor Performance,Visual Motor Coordination,Coordination, Visual Motor,Coordinations, Visual Motor,Motor Coordination, Visual,Motor Coordinations, Visual,Motor Performance, Perceptual,Motor Performance, Sensory,Motor Performances, Perceptual,Motor Performances, Sensory,Perceptual Motor Performances,Performance, Perceptual Motor,Performance, Psychomotor,Performance, Sensory Motor,Performances, Perceptual Motor,Performances, Psychomotor,Performances, Sensory Motor,Psychomotor Performances,Sensory Motor Performances,Visual Motor Coordinations
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002230 Carbidopa An inhibitor of DOPA DECARBOXYLASE that prevents conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no anti-parkinson activity by itself. Methyldopahydrazine,Carbidopa, (R)-Isomer,Carbidopa, (S)-Isomer,Lodosin,Lodosyn,MK-485,MK-486,MK 485,MK 486,MK485,MK486
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

S Iwasaki, and K Hamaguchi, and A Iwasaki, and M Takakusagi, and Y Narabayashi
March 1977, Lancet (London, England),
S Iwasaki, and K Hamaguchi, and A Iwasaki, and M Takakusagi, and Y Narabayashi
December 1970, Neurology,
S Iwasaki, and K Hamaguchi, and A Iwasaki, and M Takakusagi, and Y Narabayashi
February 1974, Journal of chronic diseases,
S Iwasaki, and K Hamaguchi, and A Iwasaki, and M Takakusagi, and Y Narabayashi
December 1970, Neurology,
S Iwasaki, and K Hamaguchi, and A Iwasaki, and M Takakusagi, and Y Narabayashi
October 2011, Movement disorders : official journal of the Movement Disorder Society,
S Iwasaki, and K Hamaguchi, and A Iwasaki, and M Takakusagi, and Y Narabayashi
January 1987, Advances in neurology,
S Iwasaki, and K Hamaguchi, and A Iwasaki, and M Takakusagi, and Y Narabayashi
March 1981, British medical journal (Clinical research ed.),
S Iwasaki, and K Hamaguchi, and A Iwasaki, and M Takakusagi, and Y Narabayashi
May 1981, British medical journal (Clinical research ed.),
S Iwasaki, and K Hamaguchi, and A Iwasaki, and M Takakusagi, and Y Narabayashi
April 1981, British medical journal (Clinical research ed.),
S Iwasaki, and K Hamaguchi, and A Iwasaki, and M Takakusagi, and Y Narabayashi
January 1987, Advances in neurology,
Copied contents to your clipboard!